Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reducing costs and improving compliance.

W W Neal1

  • 1Veterans Administration Medical Center, Dallas, Texas 75216.

The American Journal of Cardiology
|January 17, 1989
PubMed
Summary

The cost-effectiveness of antihypertensive therapy depends on balancing treatment costs against savings from preventing cardiovascular events. Expensive medications haven't proven superior to cheaper alternatives in clinical trials for blood pressure control or reducing mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of reduction in drugs or dosage after long-term control of systemic hypertension.

The American journal of cardiology·1989
Same author

Single and combined therapy for systemic hypertension with propranolol, hydralazine and hydrochlorothiazide: hemodynamic and neuroendocrine mechanisms of action.

The American journal of cardiology·1985
See all related articles

Area of Science:

  • Pharmacoeconomics
  • Cardiovascular Medicine
  • Public Health

Background:

  • Antihypertensive therapy cost-effectiveness is crucial for justifying higher-priced medications.
  • The goal is to balance treatment expenses with savings from preventing stroke and myocardial infarction.

Purpose of the Study:

  • To evaluate the cost-effectiveness of different antihypertensive drug classes.
  • To determine if more expensive agents offer superior outcomes compared to less expensive ones.

Main Methods:

  • Review of clinical trial data comparing various antihypertensive agents.
  • Analysis of cost-effectiveness based on blood pressure control, quality of life, and reduction in cardiovascular events.

Main Results:

  • Clinical trials have not demonstrated superior efficacy of expensive agents (ACE inhibitors, calcium channel blockers) over cheaper diuretics in lowering blood pressure or reducing cardiovascular morbidity/mortality.
  • Poor patient compliance significantly diminishes both treatment effectiveness and cost-effectiveness.

Conclusions:

  • The justification for using more expensive antihypertensive drugs requires evidence of better blood pressure control, improved quality of life, or reduced cardiovascular risks, which current data do not consistently support.
  • Physician intervention is vital to enhance patient compliance, optimize treatment regimens, and improve overall therapeutic outcomes and cost-effectiveness.

Related Experiment Videos